A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
© 2024. The Author(s)..
PURPOSE: TAS-117 is a highly potent and selective, oral, allosteric pan-AKT inhibitor under development for advanced/metastatic solid tumors. The safety, clinical pharmacology, pharmacogenomics and efficacy were investigated.
METHODS: This phase I, open-label, non-randomized, dose-escalating, first-in-human study enrolled patients with advanced/metastatic solid tumors and comprised three phases (dose escalation phase [DEP], regimen modification phase [RMP], and safety assessment phase [SAP]). The SAP dose and regimen were determined in the DEP and RMP. Once-daily and intermittent dosing (4 days on/3 days off, 21-day cycles) were investigated. The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 of the DEP and RMP and incidences of adverse events (AEs) and adverse drug reactions (ADRs) in the SAP. Secondary endpoints included pharmacokinetics, pharmacodynamics, pharmacogenomics, and antitumor activity.
RESULTS: Of 66 enrolled patients, 65 received TAS-117 (DEP, n = 12; RMP, n = 10; SAP, n = 43). No DLTs were reported with 24-mg/day intermittent dosing, which was selected as a recommended dose in SAP. In the SAP, 98.5% of patients experienced both AEs and ADRs (grade ≥ 3, 67.7% and 60.0%, respectively). In the dose range tested (8 to 32 mg/day), TAS-117 pharmacokinetics were dose proportional, and pharmacodynamic analysis showed a reduction of phosphorylated PRAS40, a direct substrate of AKT. Four patients in the SAP had confirmed partial response.
CONCLUSION: Oral doses of TAS-117 once daily up to 16 mg/day and intermittent dosing of 24 mg/day were well tolerated. TAS-117 pharmacokinetics were dose proportional at the doses evaluated. Antitumor activity may occur through AKT inhibition.
TRIAL REGISTRATION: jRCT2080222728 (January 29, 2015).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cancer chemotherapy and pharmacology - (2024) vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doi, Toshihiko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AKT inhibitor |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00280-023-04631-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369016874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369016874 | ||
| 003 | DE-627 | ||
| 005 | 20240229165624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00280-023-04631-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM369016874 | ||
| 035 | |a (NLM)38411735 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doi, Toshihiko |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: TAS-117 is a highly potent and selective, oral, allosteric pan-AKT inhibitor under development for advanced/metastatic solid tumors. The safety, clinical pharmacology, pharmacogenomics and efficacy were investigated | ||
| 520 | |a METHODS: This phase I, open-label, non-randomized, dose-escalating, first-in-human study enrolled patients with advanced/metastatic solid tumors and comprised three phases (dose escalation phase [DEP], regimen modification phase [RMP], and safety assessment phase [SAP]). The SAP dose and regimen were determined in the DEP and RMP. Once-daily and intermittent dosing (4 days on/3 days off, 21-day cycles) were investigated. The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 of the DEP and RMP and incidences of adverse events (AEs) and adverse drug reactions (ADRs) in the SAP. Secondary endpoints included pharmacokinetics, pharmacodynamics, pharmacogenomics, and antitumor activity | ||
| 520 | |a RESULTS: Of 66 enrolled patients, 65 received TAS-117 (DEP, n = 12; RMP, n = 10; SAP, n = 43). No DLTs were reported with 24-mg/day intermittent dosing, which was selected as a recommended dose in SAP. In the SAP, 98.5% of patients experienced both AEs and ADRs (grade ≥ 3, 67.7% and 60.0%, respectively). In the dose range tested (8 to 32 mg/day), TAS-117 pharmacokinetics were dose proportional, and pharmacodynamic analysis showed a reduction of phosphorylated PRAS40, a direct substrate of AKT. Four patients in the SAP had confirmed partial response | ||
| 520 | |a CONCLUSION: Oral doses of TAS-117 once daily up to 16 mg/day and intermittent dosing of 24 mg/day were well tolerated. TAS-117 pharmacokinetics were dose proportional at the doses evaluated. Antitumor activity may occur through AKT inhibition | ||
| 520 | |a TRIAL REGISTRATION: jRCT2080222728 (January 29, 2015) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AKT inhibitor | |
| 650 | 4 | |a Advanced solid tumor | |
| 650 | 4 | |a First-in-human | |
| 650 | 4 | |a Pharmacodynamics | |
| 650 | 4 | |a Pharmacokinetics | |
| 700 | 1 | |a Takahashi, Shunji |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yonemori, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Kosei |e verfasserin |4 aut | |
| 700 | 1 | |a Takehara, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Harano, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yunokawa, Mayu |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shimoi, Tatsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Horie, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Ogasawara, Aiko |e verfasserin |4 aut | |
| 700 | 1 | |a Okame, Shinichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d 1990 |g (2024) vom: 27. Feb. |w (DE-627)NLM00036438X |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00280-023-04631-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 02 | ||